These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 12742991)

  • 1. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones.
    Varo N; Vicent D; Libby P; Nuzzo R; Calle-Pascual AL; Bernal MR; Fernández-Cruz A; Veves A; Jarolim P; Varo JJ; Goldfine A; Horton E; Schönbeck U
    Circulation; 2003 Jun; 107(21):2664-9. PubMed ID: 12742991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
    Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
    Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels.
    Tan KT; Tayebjee MH; Lim HS; Lip GY
    Diabet Med; 2005 Dec; 22(12):1657-62. PubMed ID: 16401308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: Soluble CD40 ligand and high-sensitivity C-reactive protein.
    Guldiken S; Demir M; Arikan E; Turgut B; Azcan S; Gerenli M; Tugrul A
    Thromb Res; 2007; 119(1):79-84. PubMed ID: 16476470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
    Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial.
    Caballero AE; Saouaf R; Lim SC; Hamdy O; Abou-Elenin K; O'Connor C; Logerfo FW; Horton ES; Veves A
    Metabolism; 2003 Feb; 52(2):173-80. PubMed ID: 12601628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention.
    Lim HS; Blann AD; Lip GY
    Circulation; 2004 Jun; 109(21):2524-8. PubMed ID: 15136493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study.
    de Lemos JA; Zirlik A; Schönbeck U; Varo N; Murphy SA; Khera A; McGuire DK; Stanek G; Lo HS; Nuzzo R; Morrow DA; Peshock R; Libby P
    Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2192-6. PubMed ID: 16109925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
    Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study.
    Stakos DA; Schuster DP; Sparks EA; Wooley CF; Osei K; Boudoulas H
    J Cardiol; 2003 Apr; 41(4):183-90. PubMed ID: 12728539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between soluble CD40 ligand and gamma-glutamyltransferase concentrations in non-drinking, young Type 1 diabetic individuals.
    Zoppini G; Targher G; Trombetta M; Lippi G; Muggeo M
    Diabet Med; 2008 Nov; 25(11):1283-8. PubMed ID: 19046217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Sasiela WJ; Szarek M; Ganz P; Libby P;
    Circulation; 2004 Jul; 110(4):386-91. PubMed ID: 15262833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function.
    Lajer M; Tarnow I; Michelson AD; Jorsal A; Frelinger AL; Parving HH; Rossing P; Tarnow L
    Platelets; 2010; 21(7):525-32. PubMed ID: 20701458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-conventional markers of atherosclerosis before and after gastric banding surgery.
    Hanusch-Enserer U; Zorn G; Wojta J; Kopp CW; Prager R; Koenig W; Schillinger M; Roden M; Huber K
    Eur Heart J; 2009 Jun; 30(12):1516-24. PubMed ID: 19380349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
    De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
    J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
    Habib SS; Aslam M; Naveed AK; Razi MS
    Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus.
    Santilli F; Davì G; Consoli A; Cipollone F; Mezzetti A; Falco A; Taraborelli T; Devangelio E; Ciabattoni G; Basili S; Patrono C
    J Am Coll Cardiol; 2006 Jan; 47(2):391-7. PubMed ID: 16412866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated circulating levels of soluble CD-40 ligand in haemodialysis patients with symptomatic coronary heart disease.
    Lim PS; Wu MY; Chien SW; Wu TK; Liu CS; Hu CY; Chang HC; Pai MA
    Nephrology (Carlton); 2008 Dec; 13(8):677-83. PubMed ID: 19019166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of low-grade inflammation and platelet activation in patients with hypertension with microalbuminuria.
    Ferroni P; Guagnano MT; Falco A; Paoletti V; Manigrasso MR; Michetti N; Santilli F; Guadagni F; Basili S; Davì G
    Clin Sci (Lond); 2008 Mar; 114(6):449-55. PubMed ID: 17988217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.